Related Experiment Videos
Salirasib in the treatment of pancreatic cancer
Ernesto Bustinza-Linares1, Razelle Kurzrock, Apostolia-Maria Tsimberidou
1Department of Investigational Cancer Therapeutics, The Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
The Ras family of genes is involved in the cellular regulation of proliferation, differentiation, cell adhesion and apoptosis. The K-ras gene is mutated in over 90% of pancreatic cancer cases. Salirasib (S-trans,trans-farnesylthiosalycilic acid [FTS]) is a synthetic small molecule that acts as a potent Ras inhibitor. It is a farnesylcysteine mimetic that selectively disrupts the association of active RAS proteins with the plasma membrane. Animal studies demonstrated that salirasib inhibited tumor growth, downregulated gene expression in the cell cycle and Ras signaling pathways. In a clinical study of salirasib combined with standard doses of gemcitabine, it was demonstrated that the two drugs have no overlapping pharmacokinetics. The salirasib recommended dose was 600 mg twice daily and the progression-free survival was 4.7 months. Future studies will determine whether salirasib adds to the anti-tumor activity of drugs approved by the US FDA for pancreatic cancer.
Insights
Salirasib, a Ras inhibitor, showed potential in pancreatic cancer treatment by disrupting Ras signaling. Clinical trials combined it with gemcitabine, demonstrating a progression-free survival of 4.7 months.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras genes regulate crucial cellular processes like proliferation and apoptosis.
- K-ras gene mutations are prevalent in over 90% of pancreatic cancer cases.
- Targeting Ras signaling is a key strategy in pancreatic cancer therapy.
Purpose of the Study:
- To evaluate Salirasib (S-trans,trans-farnesylthiosalycilic acid [FTS]), a novel Ras inhibitor.
- To assess the safety and efficacy of Salirasib in combination with gemcitabine for pancreatic cancer.
- To investigate the pharmacokinetic profile of Salirasib and gemcitabine combination therapy.
Main Methods:
- Salirasib, a farnesylcysteine mimetic, was administered to disrupt active RAS protein-cell membrane association.
- Animal studies assessed tumor growth inhibition and modulation of cell cycle and Ras pathways.
- A clinical study evaluated Salirasib combined with gemcitabine, analyzing pharmacokinetics and progression-free survival.
Main Results:
- Animal studies showed Salirasib inhibited tumor growth and downregulated key signaling pathways.
- The combination of Salirasib and gemcitabine exhibited no overlapping pharmacokinetics.
- The recommended dose of Salirasib was 600 mg twice daily, yielding a progression-free survival of 4.7 months.
Conclusions:
- Salirasib demonstrates anti-tumor activity by inhibiting Ras signaling pathways.
- The combination therapy with gemcitabine is pharmacokinetically compatible.
- Further research is warranted to determine Salirasib's added benefit in FDA-approved pancreatic cancer treatments.
